MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Sells 852 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lessened its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 1.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 59,887 shares of the company’s stock after selling 852 shares during the quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. owned 0.07% of IDEXX Laboratories worth $24,760,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of the company. Geode Capital Management LLC increased its position in IDEXX Laboratories by 1.7% during the fourth quarter. Geode Capital Management LLC now owns 2,297,271 shares of the company’s stock valued at $948,279,000 after acquiring an additional 37,734 shares during the last quarter. Bamco Inc. NY increased its position in IDEXX Laboratories by 4.3% during the fourth quarter. Bamco Inc. NY now owns 2,005,522 shares of the company’s stock valued at $829,163,000 after acquiring an additional 82,264 shares during the last quarter. Invesco Ltd. increased its position in IDEXX Laboratories by 6.8% during the fourth quarter. Invesco Ltd. now owns 1,160,988 shares of the company’s stock valued at $479,999,000 after acquiring an additional 74,324 shares during the last quarter. Norges Bank purchased a new stake in IDEXX Laboratories during the fourth quarter valued at $412,258,000. Finally, Northern Trust Corp increased its position in IDEXX Laboratories by 18.6% during the fourth quarter. Northern Trust Corp now owns 912,874 shares of the company’s stock valued at $377,419,000 after acquiring an additional 143,369 shares during the last quarter. Hedge funds and other institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Stock Performance

NASDAQ:IDXX opened at $509.42 on Thursday. The company has a current ratio of 1.31, a quick ratio of 0.95 and a debt-to-equity ratio of 0.28. IDEXX Laboratories, Inc. has a 12-month low of $356.14 and a 12-month high of $548.88. The stock has a 50-day moving average price of $427.95 and a 200 day moving average price of $430.50. The stock has a market capitalization of $40.97 billion, a P/E ratio of 47.74, a P/E/G ratio of 3.41 and a beta of 1.52.

IDEXX Laboratories (NASDAQ:IDXX) last released its earnings results on Thursday, May 1st. The company reported $2.96 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.93 by $0.03. IDEXX Laboratories had a return on equity of 55.82% and a net margin of 22.78%. The firm had revenue of $998.43 million during the quarter, compared to analysts’ expectations of $998.25 million. During the same quarter last year, the business posted $2.71 earnings per share. The firm’s revenue was up 3.6% on a year-over-year basis. Equities research analysts forecast that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts recently commented on IDXX shares. Piper Sandler upped their price objective on IDEXX Laboratories from $435.00 to $510.00 and gave the company a “neutral” rating in a research report on Monday, February 10th. Morgan Stanley upped their price target on IDEXX Laboratories from $548.00 to $558.00 and gave the stock an “overweight” rating in a research report on Monday, May 5th. Bank of America upped their price target on IDEXX Laboratories from $475.00 to $535.00 and gave the stock a “neutral” rating in a research report on Tuesday, February 4th. Barclays upped their price target on IDEXX Laboratories from $481.00 to $520.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 4th. Finally, Stifel Nicolaus reduced their price target on IDEXX Laboratories from $450.00 to $420.00 and set a “hold” rating for the company in a research report on Monday, April 14th. Three research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $524.75.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.